Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98%
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pluri Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Net Change in Cash
-$1.9m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
4%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Net Change in Cash
-$3.2m
CAGR 3-Years
-94%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Net Change in Cash
$19.4m
CAGR 3-Years
-26%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Net Change in Cash
$5.9m
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Net Change in Cash
-$693k
CAGR 3-Years
N/A
CAGR 5-Years
39%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Net Change in Cash
-â‚Ş24.8m
CAGR 3-Years
N/A
CAGR 5-Years
-33%
CAGR 10-Years
N/A
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Net Change in Cash?
Net Change in Cash
-1.9m USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Net Change in Cash amounts to -1.9m USD.

What is Pluri Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
4%

Over the last year, the Net Change in Cash growth was 50%.

Back to Top